Loading stock data…
$4.21-0.17 (-3.88%)
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
Sionna Therapeutics, Inc. in the Healthcare sector is trading at $4.21 with a market capitalization of $324M. Wall Street consensus targets $21.00 (7 analysts), implying a +398.8% move over the next 12 months. The stock is currently near its 52-week low of $4.01, remaining 86.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$32.47M↓ | -$29.60M↓ | -$23.61M↑ | -$23.80M↓ | -$21.91M |
| Net Income | -$29.89M↓ | -$26.78M↓ | -$20.44M↓ | -$20.28M↓ | -$18.07M |
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmemb...